LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits.

doi:10.1126/scitranslmed.aav0820

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits.

Science translational medicine - 22 Apr 2020

Baptista Marco A S, Merchant Kalpana, Barrett Ted, Bhargava Sakshi, Bryce Dianne K, Ellis J Michael, Estrada Anthony A, Fell Matthew J, Fiske Brian K, Fuji Reina N, Galatsis Paul, Henry Anastasia G, Hill Sue, Hirst Warren, Houle Christopher, Kennedy Matthew E, Liu Xingrong, Maddess Matthew L, Markgraf Carrie, Mei Hong, Meier William A, Needle Elie, Ploch Stephen, Royer Christopher, Rudolph Karin, Sharma Alok K, Stepan Antonia, Steyn Stefan, Trost Craig, Yin Zhizhang, Yu Hongshi, Wang Xiang, Sherer Todd B

Abstract excerpt

The kinase-activating mutation G2019S in leucine-rich repeat kinase 2 (LRRK2) is one of the most common genetic causes of Parkinson's disease (PD) and has spurred development of LRRK2 inhibitors. Preclinical studies have raised concerns about the safety of LRRK2 inhibitors due to histopathological changes in the lungs of nonhuman primates treated with two of these compounds. Here, we investigated whether these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung

Share to Morpholines

Share to Mutation

Share to Parkinson Disease

Share to Primates

Share to Pyrimidines

Share to Pyrroles

Source

Open in PubMed

Identifiers

PMID: 32321864
DOI: 10.1126/scitranslmed.aav0820

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits.PMID 32321864Read ↗

LRRK2 kinase inhibitors induce a reversible effect in the lungs of non-human primates with no measurable pulmonary deficitsSemantic proximity Read ↗

G2019S LRRK2 Kinase Inhibition in Heterozygous Mice Avoids Lung Phenotype Observed with Inhibition of WT LRRK2.Semantic proximity Read ↗

Discovery of Highly Potent, Selective, and Brain-Penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule InhibitorsSemantic proximity Read ↗

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.Semantic proximity Read ↗

Behavioral phenotypes associated with MPTP induction of partial lesions in common marmosets (Callithrix jacchus).Semantic proximity Read ↗

Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivoSemantic proximity Read ↗

Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.Semantic proximity Read ↗

Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.